| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000027751 |
| Receipt No. | R000031802 |
| Official scientific title of the study | A Study on the efficacy of BVVR001 (development code) |
| Date of disclosure of the study information | 2017/06/14 |
| Last modified on | 2017/12/14 (Ver. 2) |
| Basic information | |||
| Official scientific title of the study | A Study on the efficacy of BVVR001 (development code) | ||
| Title of the study (Brief title) | A Study on the efficacy of BVVR001 (development code) | ||
| Region |
|
||
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To confirm the efficacy of BVVR001 (development code) for the skin microcirculation |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Objective indicators on skin microcirculation before and after ingestion of BVVR001 (development code) for 4 weeks |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | BVVR001 (development code) ingestion
Twice a day (before bedtime and after wake-up) for 4 weeks -> Washout for 5 weeks -> Placebo ingestion Twice a day (before bedtime and after wake-up) for 4 weeks |
|
| Interventions/Control_2 | Placebo ingestion
Twice a day (before bedtime and after wake-up) for 4 weeks -> Washout for 5 weeks -> BVVR001 (development code) ingestion Twice a day (before bedtime and after wake-up) for 4 weeks |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | Healthy males | |||
| Key exclusion criteria | -Subjects who have been suffered from a critical disease
-Subjects who take prescription medicine -Subjects with the illness of a vascular function -Subjects with atopic dermatitis, eczema and pollen allergy -Subjects with food allergy -Subjects with smoking habit -Subjects who are in poor physical condition -Subjects who have an abnormality of measurement skin site -Subjects undergoing trauma in the measurement site -Subjects who are influenced by the adhesive -Subjects who participate in the other examinations which have an influence on this examination -Subjects deemed inappropriate to participate in this study by the principle investigator |
|||
| Target sample size | 25 | |||
| Research contact person | |
| Name of lead principal investigator | Akihiko Fujii |
| Organization | Kao Corporation |
| Division name | R&D -Core Technology- Biological Science Research |
| Address | 2606, Akabane, Ichikai-machi, Haga-gun, Tochigi, 321-3497, JAPAN |
| TEL | +81-285-68-7458 |
| fujii.akihiko@kao.co.jp | |
| Public contact | |
| Name of contact person | Daiji Kagawa |
| Organization | Kao Corporation |
| Division name | R&D -Core Technology- Biological Science Research |
| Address | 2606, Akabane, Ichikai-machi, Haga-gun, Tochigi, 321-3497, JAPAN |
| TEL | +81-285-68-7458 |
| Homepage URL | |
| kagawa.daiji@kao.co.jp | |
| Sponsor | |
| Institute | Kao Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 花王株式会社栃木事業場(栃木県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031802 |